Allopurinol Therapy for Gout Management

Primary Indications

Allopurinol is indicated for patients with recurrent acute gout attacks, arthropathy, tophi, or radiographic changes of gout 1, 2

The therapeutic goal of allopurinol therapy is to maintain serum uric acid below 6 mg/dL to promote crystal dissolution and prevent crystal formation 1, 3
For patients with severe gout, a lower target of <5 mg/dL is recommended until total crystal dissolution occurs 3
Allopurinol should be started at a low dose and gradually increased by 100 mg every 2-4 weeks until the target serum uric acid level is reached 1, 2

The American College of Rheumatology recommends allopurinol as the preferred first-line agent for all patients with gout, including those with moderate to severe chronic kidney disease 4

Regular monitoring of serum urate during dose titration is recommended 2
Once the target serum urate is achieved, monitoring should continue every 6 months to ensure maintenance of target levels and assess adherence 5, 4
Monitor for adverse effects, particularly hypersensitivity reactions, which can include rash, pruritis, elevated hepatic transaminases, and eosinophilia 2

Concomitant anti-inflammatory prophylaxis is strongly recommended during the first months of allopurinol therapy to prevent acute gout flares 1, 4
Prophylaxis should typically be continued for 3-6 months 4

Discontinuing allopurinol after achieving symptom control can lead to recurrence of gout attacks in approximately 87% of patients within 5 years 5, 4
Relying solely on the standard 300 mg dose can fail to achieve target urate levels in more than half of gout patients 2

The primary goal is to maintain serum uric acid below 6 mg/dL to promote crystal dissolution and prevent crystal formation, as recommended by the European League Against Rheumatism, based on evidence from the Annals of the Rheumatic Diseases 6
Allopurinol should be started at a low dose and gradually increased until the target serum uric acid level is reached, with a dosing strategy supported by evidence from the Annals of the Rheumatic Diseases 7, 6

The American College of Physicians systematic review found that once gout has been asymptomatic for 5 years, urate-lowering therapy might be discontinued, but this often leads to recurrence, with evidence suggesting a high recurrence rate 8, 9
One cohort study suggested that after 5 years of being asymptomatic, some patients might maintain acceptable urate levels for several years after discontinuation, according to research published in the Annals of Internal Medicine 8